Author Archives: admin

Comparing the Rate of Pneumonitis Associated with Treatment with PD-1 and PD-L1 Inhibitors in Patients with Lung Cancer

Treatment with the PD-1 and PD-L1 immune checkpoint inhibitors has been shown to be effective in patients with non-small cell lung cancer (NSCLC). However, treatment with these immunotherapy agents has also been associated with potentially fatal immune-related pneumonitis. To determine if pneumonitis was more frequently associated with one form of treatment, Monica Khunger, MD, and colleagues at the Cleveland Clinic, ... Read More »

Neutropenia Risk in Patients with Breast Cancer Treated with Palbociclib

The cyclin-dependent kinase-4 and -6 inhibitor palbociclib improves progression-free survival in patients with estrogen receptor-positive, metastatic breast cancer (and potentially in other forms of cancer, as well). However, treatment with palbociclib is also associated with severe neutropenia (grade 3 or 4), which can affect treatment adherence and overall outcomes. To better understand the overall risk of palbociclib-associated neutropenia, Yan Mao ... Read More »

Do Older Patients with Advanced NSCLC Treated in Clinical Trials Experience Better Outcomes than Patients Treated with Standard Therapy?

Standard thinking holds that patients with cancer who are treated in clinical trials experience greater survivability and other positive outcomes compared to their counterparts treated with standard therapy. To see if this phenomenon is valid, Ana Laura Ortega Granados and colleagues at Complejo Hospitalario de Jaén, in Jaén, Spain, conducted a retrospective case-control study comparing outcomes in patients with advanced ... Read More »

Identification of Candidates for Radical Prostatectomy with TPMB

San Diego—The identification of men with prostate cancer who are best suited for radical prostatectomy may be aided by use of intra-prostatic staging by transperineal mapping biopsy (TPMB). E. David Crawford, MD, and colleagues recently conducted an analysis of transrectal ultrasonography (TRUS) biopsy positive men with minimal disease, biopsy negative, and biopsy naïve men who had TPMB followed by radical ... Read More »

IMAAGEN Trial Secondary End Points Updated

San Diego—Researchers led by Charles Ryan, MD, presented updated results of secondary end points of the IMAAGEN (Impact of Abiraterone Acetate in Prostate Specific Antigen) study at the AUA 2016 Annual meeting during a session titled Impact of Abiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on Prostate-Specific Antigen and Radiographic Disease ... Read More »

CTC Cells Predictors of Survival in Men Treated with Abiraterone Acetate

San Diego—Among patients with metastatic castration resistant prostate cancer (mCRPC), circulating tumor cells (CTCs) are established biomarkers to predict response to chemotherapy. A recent biomarker panel comprising CTC has also demonstrated predictive value for survival in men treated with abiraterone acetate following chemotherapy in the COU-AA-301 pivotal trial. Researchers led by Christian Meyer, MD, presented long-term data of a sub-analysis ... Read More »

Abiraterone Acetate Provides Survival Benefit in Post-Chemotherapy Setting

San Diego—In a retrospective cohort study conducted by Alice Dragomir, MSc, PhD, and colleagues, there was survival benefit among patients with metastatic castration resistant prostate cancer (mCRPC) receiving abiraterone acetate in combination with chemotherapy compared with patients receiving chemotherapy only. The researchers reported results of the study at the AUA 2016 Annual Meeting in a presentation titled Use of Abiraterone ... Read More »

Researchers Develop Gene Classifier to Aid Treatment Decisions

San Diego—With the increasing use of precision medicine, there has not yet been a broad impact of genomic classifications of prostate cancer on patient care, according to researchers led by Sungyong You, PhD. The research team presented results of an integrative analysis of 14 disease-related pathways in more than 4600 clinical specimens and 25 prostate cancer preclinical models during a ... Read More »

Disadvantages of PSA Screening Mentioned Less in Decision-Making Process

San Diego—Screening for prostate cancer based on prostate specific antigen level is a controversial issue in the United States. Several guidelines and healthcare organizations, including the American Urological Association, recommend counseling and shared-decision making for patients considering PSA screening. Researchers, led by Nawar Hanna, MD, recently conducted an analysis to identify patient characteristics associated with physician counseling. They reported results ... Read More »

PSA Screening Rates Drop after 2011 USPSTF Recommendations

San Diego—Given concerns about over-diagnosis and over-treatment of prostate cancer in the United States, there is ongoing debate regarding prostate specific antigen (PSA) screening. In 2011, the United States Preventive Services Task Force (USPSTF) released a draft of recommendations advising against PSA screening in all men (the draft was finalized in May 2012). Firas Abdollah, MD, and colleagues recently conducted ... Read More »